150
Participants
Start Date
December 31, 2014
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2018
RBX2660 (microbiota suspension)
A suspension of intestinal microbes
Placebo
A suspension of saline and cryoprotectant
New York-Presbyterian Hospital/Weill Cornell Medical College, New York
New York Hospital Queens, Flushing
Gastroenterology Group of Rochester, Rochester
Hospital of the University of Pennsylvania, Philadelphia
Chevy Chase Clinical Research, Chevy Chase
Borland-Groover Clinic, Jacksonville
Louis Stokes Cleveland VA Medical Center, Cleveland
Regional Infectious Diseases and Infusion Center, Lima
Infectious Diseases of Indiana, Indianapolis
Henry Ford Health System, Detroit
Regions Hospital, Saint Paul
Mayo Clinic Minnesota, Rochester
Sanford Health, Fargo
Loyola University Chicago, Chicago
University of Chicago, Chicago
Washington University School of Medicine, St Louis
University of Colorado, Aurora
Grand Teton Research Group, Idaho Falls
Mayo Clinic Arizona, Phoenix
University of British Columbia, Vancouver
St. Joseph's Hospital, Hamilton
Rebiotix Inc.
INDUSTRY